 |
- Mundipharma will provide Emtrix® for patients suffering from nail fungus and nail psoriasis in the Middle East and Africa.
- Rights secured in agreement with Swedish company Moberg Pharma, a specialist in topical treatments for nail and skin diseases.
- Emtrix® to be distributed in the region under Mundipharma’s popular BETADINE® brand.
DUBAI, United Arab Emirates, Nov. 7, 2018 /PRNewswire/ — Mundipharma has signed an agreement with Moberg Pharma to commercialize Emtrix® — its leading product for nail fungus and nail psoriasis — in the Middle East and Africa under Mundipharma’s BETADINE® consumer healthcare brand.
Fungal infections can cause onychomycosis, which can result in thickening, splitting, roughening and discoloration of both toenails and fingernails. It is estimated that about 2% to 13.8% of adults are affected by onychomycosis,[I], [ii], [iii] and the prevalence increases with age reaching 25 – 30% in the elderly.[iv], [v] Infections can be painful, impact a patient’s self-image and are associated with increased risk of secondary infection. Left untreated, it can cause serious limitations to mobility.[vi]
Applied to deformed nails resulting from fungal infection, such as onychomycosis, as well as psoriasis that occurs in nails, Emtrix® improves the appearance of damaged nails by reducing discoloration, normalizing thickness, and hydrating brittle nails. [vii], [viii], [ix],[x]
Mundipharma CEO, Raman Singh, said: “This agreement is another example of Mundipharma expanding its operations to provide better healthcare options for more patients. Many more people will now be able to access one of the leading products for these common and uncomfortable conditions.
“This addition complements Mundipharma’s existing portfolio of BETADINE®^ treatments, including infection control products, which have been trusted by healthcare professionals and consumers around the world for over 50 years.”
“We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets”, says Peter Wolpert, Moberg Pharma’s CEO.
|
[i] |
Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172–3. |
|
[ii] |
Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703. |
|
[iii] |
Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641–8. |
|
[iv] |
Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703. |
|
[v] |
Emtestam et al. Mycoses 2012, Vol 55:532-540. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. |
|
[vi] |
Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172–3. |
|
[vii] |
Emtestam et al. Mycoses 2012, Vol 55:532-540. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. |
|
[viii] |
Faergemann et al. Journal of Cosmetics, Dermatological Sciences and Applications 2011, Vol 1:59-63. Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis. |
|
[ix] |
Hultenby et al. Mycoses 2014, Vol 57:630-638. The Effect of K101 Nail Solution on Trichophyton rubrum and Candida albicans growth and ultrastructure. |
|
[x] |
Piraccini BM, Starace M, Toft A. Dermatology. 2017;233(2-3):178-183. Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis. |
|
^ |
Povidone-Iodine containing products |
About Mundipharma
Mundipharma is a network of independent associated companies, which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 30 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast® and Domeboro®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
For more information, please visit: www.mobergpharma.com
Photo – https://photos.prnasia.com/prnh/20181106/2290778-1LOGO
